Business
CORRECTING and REPLACING: Immune Therapeutics, Inc.
CORRECTING and REPLACING: Immune Therapeutics, Inc..
About this update from Biostax Corp.
[{"type":"text","content":"\n\n In a release issued under the same headline earlier today by Immune Therapeutics, Inc. (OTCQB:IMUN), the headline has been corrected to read \"Immune Therapeutics Announces NAFDAC Approval for Marketing and Distribution of Lodonal™ for the Treatment of HIV in Nigeria,\" not \"Immune Therapeutics Announces NAFDAC Approval Lodonal™ for the Treatment of HIV in Nigeria\" as previously stated. The corrected release follows:\n Immune Therapeutics Announces NAFDAC Approval for Marketing and Distribution of Lodonal™ for the Treatment of HIV in Nigeria Immune Therapeutics Emerges as a Key Player in Immunotherapy Field Highlights: National Agency for Food and Drug Administration and Control (“NAFDAC”) approval paves way for Immune Therapeutics’ first significant revenue channel Immune Therapeutics’ goal to capture 20% share of Nigeria’s billion-dollar HIV/AIDS treatment market Lodonal to represent a significant “breakthrough” as the first affordable, non-toxic adjunct therapy for HIV/AIDSCompany expected to strengthen management team to spearhead commercialization throughout AfricaWith initial contracts expected shortly, company on-track to meet guidance of achieving profitability by end of current fiscal year ORLANDO, Fla., May 22, 2017 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (OTCQB:IMUN), a specialty pharmaceutical company focused on developing and commercializing its novel patented, affordable, non-toxic therapy for the treatment of cancer, HIV, autoimmune disease, and other inflammatory conditions, today announced that it has received NAFDAC (National Agency for Food and Drug Administration and Control) approval to market and distribute LodonalTM, the Company’s breakthrough treatment for HIV/AIDS in Nigeria. The Company and its strategic partners plan to immediately initiate sales activities of this first-to-market opportunity. The approval is for a one-day Immune System Regulator for the management of HIV/AIDS, which is based on the results of the Company’s 90-Day bridging trial in Nigeria that resulted in a 44% increase in CD4 Count versus an 11% increase for standard of care patients.  Additionally, there was a reduction in opportunistic infections plus several Phase II multi-center, randomized studies that demonstrated improvemen...